Semaglutide denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Semaglutide as Duplicate Therapy

A duplicate-therapy denial from Humana means that Humana's review process has identified another active prescription claim for a medication it considers therapeutically equivalent to semaglutide — most commonly another GLP-1 receptor agonist or another agent approved for the same indication. Humana applies this denial as part of its pharmacy benefit management to prevent concurrent authorization of medications it treats as interchangeable.

This type of denial can arise from an error in Humana's claims data (a prior prescription still appearing as active when it has been discontinued), or it can reflect a genuine concurrent claim. Identifying the specific medication Humana believes duplicates semaglutide is essential — that information should be in the denial letter.

## Why This Denial Is Appealable

Duplicate-therapy logic relies entirely on the accuracy of Humana's records. If the identified medication is no longer active, was never intended to treat the same condition, has been discontinued due to inadequate response or intolerance, or is not therapeutically substitutable for your specific clinical situation, the factual basis for the denial does not hold. Prescribers frequently have documented clinical reasons why two agents in the same class are not interchangeable for a specific patient — differences in indication, formulation, route, tolerability, or comorbid factors.

## Your Federal Appeal Rights

• Internal appeal: You are entitled to a full-and-fair internal review under ERISA §503 (employer-sponsored plans) or applicable state law (individual and fully-insured plans). The deadline for filing is shown on your denial notice — do not miss it.
• External review: Under ACA §2719, if the internal appeal results in an adverse determination, you may request review by an independent review organization (IRO). The external-review window is generally approximately four months from the date of the final internal denial; verify the exact date on your denial letter.
• Expedited review: Request expedited internal and external review simultaneously if delay would seriously jeopardize your health.

## Documentation to Gather

1. Identify the alleged duplicate: The denial letter should name the medication Humana considers a duplicate. Confirm with your prescriber whether that medication is still active, for what indication it was prescribed, and whether it has been discontinued. 2. Active medication list: A current, dated medication list signed by your prescriber confirming which medications are genuinely active and for which specific indications. 3. Discontinuation records: Pharmacy fill history and chart notes showing the last fill date and documented reason for stopping the alleged duplicate, if applicable. 4. Separate-indication documentation: If the other medication treats a different condition, provide diagnosis codes and chart documentation supporting distinct indications for each drug. 5. Clinical non-interchangeability letter: A signed letter from your prescriber explaining the clinical basis for semaglutide's necessity and why the identified medication does not serve as an adequate substitute for you — citing tolerability, efficacy history, comorbidities, or other documented clinical factors.

## Criteria-Mapping Structure

Obtain Humana's published coverage policy or pharmacy benefit criteria for semaglutide and for duplicate-therapy edits. Address each criterion with specific chart evidence:

| Humana Duplicate-Therapy Criterion | Your Chart Evidence | |------------------------------------|--------------------| | Is the identified agent currently active? | [Discontinuation date or confirmation of non-overlap] | | Is it prescribed for the same indication as semaglutide? | [Separate diagnosis codes and prescriber attestation] | | Is there a documented clinical reason for non-interchangeability? | [Prescriber letter citing specific clinical basis] | | Does the prescriber attest semaglutide is independently necessary? | [Signed medical-necessity letter, date] |

A direct, criterion-matched response supported by accurate, dated chart records is the most effective way to overturn a duplicate-therapy denial.